Information Provided By:
Fly News Breaks for June 1, 2016
BMRN
Jun 1, 2016 | 08:23 EDT
SunTrust cut its price target on BioMarin after the company announced that it would no longer seek EU approval for its DMD drug. However, the firm thinks that the company has a number of positive catalysts in 2016, and it reiterates a Buy rating.